Miroslawa Nowak, MD

Bristol Myers Squibb
Princeton, NJ, United States

Research & Development, Immunology, Bristol Myers Squibb

Presentation(s):

• 1418: Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial

  Monday, November 13, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.